Caly für 0,49 und keiner kauft !
Ich hoffe es geht dir gut !
Gruß
leo
Ich geh aber vorsichtig erst mal rein ( bisse Schnuppern )
Die Zahlen ? Keine Ahnung !
Die Liquität reicht ja bis Ende 2004 spätestens dann muss was kommen.....
Wird bestimmt Lustig
MfG
Calyritter
www.heinertreff.de
Könnte ein guter Zock werden ..............
Calyritter
www.heinertreff.de
Mittlerweile steht sie ja auf 0,24 cent !!!!
Orasure hat uns am Freitag ein ganz grossen Schaden zugeführt mit ihrem Speicheltest !!!
Schauen wir mal wie es weiterghet, vor allem muss jetzt Caly schnellstens kontern denn wenn Orasure sich einen Namen mit ihrem Speicheltest machen wird für die Urin Probe nich viel Intresse übrigbleiben.
Meiner Meinung sieht es nicht mehr so rosig aus ........
hmm
Das ganze ist auch eine Preisfrage denke ich.
Auf jedenfall war das der 4. Test der 0,50
jetzt geht es los meiner Meinung nach.
Medizin
In den USA hat die Gesundheitsbehörde FDA den ersten oralen HIV-Schnelltest zugelassen. Es ist bereits der zweite Schnelltest auf dem Markt, für den anderen muss dem Patienten jedoch ein wenig Blut entnommen werden. Bei dem neuen Test streichen Ärzte oder Pfleger dem Patienten mit einem Wattestab über den Gaumen. Der Wattestab kommt dann in ein Teströhrchen und liefert nach 20 Minuten das Ergebnis. Die FDA hofft, dass sich mehr Angehörige der Risikogruppen auf HIV testen lassen. Bislang scheuten einige offenbar vor Bluttests zurück. Patienten mit positivem Ergebnis müssen die Diagnose jedoch mit einem Bluttest bestätigen lassen. AP
Mit der Vermarktung ist Caly deutlich im Vorsprung.
Hier ein Thread aus dem Raging Bull Board:
Calypte Biomedical Corporation (OTCBB: CYPT),a developer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, announced fourth quarter and year-end results last week for the period ended December 31, 2003. For the first time in its history, the company did not have a “going concern” opinion from its auditors. Calypte recorded Q4 revenues of $1,037,000, compared with $809,000 in the fourth quarter of 2002. Notably, Marr Group, one of the company’s largest investors, expanded its loan facility with the company to $15 million. CYPT also continues to consolidate its manufacturing operations into a single facility at its Rockville, Maryland location. The closing of its Alameda facility, expected to be completed by the end of the second quarter, is likely to save the company $1 million annually. Last week, OraSure announced that it had received U.S. Food and Drug Administration approval of its OraQuick® Rapid HIV Antibody Test for use with oral fluid, making it the test the first and only rapid HIV test to be approved in the U.S. by the FDA for use with oral fluid. The move could have favorable implications for CYPT, as it removes some of the risk from the approval process for the company’s rapid urine test, since the FDA has already approved another rapid HIV test. The stock fell 7 cents last week, closing at $0.50.
Grüße, ZN
Euch weiterhin viel Glück, werdet es brauchen.
Gruß RG
Bei 900.000 Shares zeigt es doch nur das die Hosenscheisser abspringer mehr nicht.
Ich habe einige Order auf 0,35 zum kauf gesetzt mehr sage ich hier erst mal nicht !!!!
Ich meine der Caly – Test ist wesentlich billiger.
Hier die Original Nachricht von der „Konkurrenz“:
26 March 2004, 4:55pm ET
By LAURAN NEERGAARD AP Medical Writer
WASHINGTON (AP) -- On-the-spot testing for the AIDS virus is getting easier: The government has approved the first oral HIV test that gives results in 20 minutes.
Shares of the test's manufacturer surged 19 percent on the news.
Until now, rapid HIV testing required pricking a person's finger to test a spot of blood.
With the new alternative from OraSure Technologies Inc., health workers simply wipe a treated cotton swab along the gums, picking up not saliva but cells lining the mouth.
Just as they do with OraSure's rapid blood test, workers then put the swab into a sticklike testing device. Infection is signaled by the presence of reddish-purple lines that appear in a window on the dipstick-like device.
About one-fourth of the 850,000 to 950,000 Americans living with HIV don't know it, according to the Centers for Disease Control and Prevention.
The rapid blood test was hailed when it won approval in November 2002 as a way to dramatically increase the number of people who know they are infected. Until then, routine HIV tests took up to two weeks to provide results, and 8,000 people a year who tested positive at public clinics never returned to get the news.
The rapid oral test may further expand efforts to get more high-risk people tested _ because some people shun blood tests and because needle-free testing is safer for health workers, too.
"This oral test provides another important option for people who might be afraid of a blood test," Health and Human Services Secretary Tommy Thompson said in announcing the Food and Drug Administration's approval on Friday. "It will improve care for these people, and improve the public health as well."
Such testing is crucial not just so patients can seek HIV treatment, but because people who know they're infected usually take steps to prevent transmission to their sexual partners, added CDC's Dr. Dixie Snider.
Mentioned Last Change§
OSUR 10.73 1.03dollars or (10.61%)
Just like the rapid blood test, the rapid oral test is more than 99 percent accurate, the FDA said. But people who test positive will need an additional laboratory-run test to confirm HIV infection.
Both tests are called OraQuick.
Shares of OraSure Technologies traded up $1.55 to close at $9.70 on the Nasdaq Stock Market.
The new oral test is "physically the same device" as the rapid blood test, but "much simpler to use," said OraSure chief executive Mike Gausling.
Thus, it will sell for the same price, about $8 per test for public health officials and $8 to $20 for other organizations, depending on the number ordered.
The CDC is expected to be a prime purchaser; the agency already has bought half a million of OraSure's OraQuick rapid blood tests in the past year.
About 40,000 Americans a year are believed to become infected with HIV, a rate that has held constant for years. Worse, there are disturbing signs that efforts to fight the epidemic are waning, such as recent increases in new HIV cases among gay men.
So last April, the CDC ordered some changes _ including a strong emphasis on using rapid tests to screen for HIV in homeless shelters, drug treatment centers, jails and other non-medical settings.
Hospitals also are prime users of rapid HIV tests, using them mostly to tell if health workers were exposed to HIV-infected blood and thus need HIV-blocking medicine. Hospitals also rapid-test women in labor who weren't checked for HIV earlier in pregnancy, so newborns of infected mothers can get anti-HIV drugs in hopes of keeping them virus-free.
Oral HIV testing already is popular with health workers _ OraSure has long sold a version that required a laboratory to give results. In about five years, oral testing took over about 30 percent of the traditional HIV testing market, Gausling said.
But it will take OraSure a few more months to be able to sell the rapid version of the oral test outside of hospitals and large health clinics. A law restricts who can use certain types of medical tests, and it will take a waiver of that law to allow the oral test to be sold in the same non-medical settings _ like mobile testing vans and homeless shelters _ that rapid blood tests already are.
Thompson said rapid oral testing also could help international efforts to fight HIV in Africa, which is particularly hard-hit by the epidemic.